Target engagement in an alzheimer trial: Crenezumab lowers amyloid ? oligomers in cerebrospinal fluid.
Ontology highlight
ABSTRACT: OBJECTIVE:Oligomeric forms of amyloid ? protein (oA?) are believed to be principally responsible for neurotoxicity in Alzheimer disease (AD), but it is not known whether anti-A? antibodies are capable of lowering oA? levels in humans. METHODS:We developed an ultrasensitive immunoassay and used it to measure oA? in cerebrospinal fluid (CSF) from 104 AD subjects participating in the ABBY and BLAZE phase 2 trials of the anti-A? antibody crenezumab. Patients received subcutaneous (SC) crenezumab (300mg) or placebo every 2 weeks, or intravenous (IV) crenezumab (15mg/kg) or placebo every 4 weeks for 68 weeks. Ninety-eight of the 104 patients had measurable baseline oA? levels, and these were compared to levels at week 69 in placebo (n = 28), SC (n = 35), and IV (n = 35) treated patients. RESULTS:Among those receiving crenezumab, 89% of SC and 86% of IV patients had lower levels of oA? at week 69 versus baseline. The difference in the proportion of patients with decreasing levels was significant for both treatment arms: p =?0.0035 for SC and p = 0.01 for IV crenezumab versus placebo. The median percentage change was -48% in the SC arm and -43% in the IV arm. No systematic change was observed in the placebo group, with a median change of -13% and equivalent portions with negative and positive change. INTERPRETATION:Crenezumab lowered CSF oA? levels in the large majority of treated patients tested. These results support engagement of the principal pathobiological target in AD and identify CSF oA? as a novel pharmacodynamic biomarker for use in trials of anti-A? agents. ANN NEUROL 2019;86:215-224.
SUBMITTER: Yang T
PROVIDER: S-EPMC6771589 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA